Opioid Withdrawal Clinical Trial
Official title:
5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence
Opioid medications are commonly used for pain relief. When given over time, physical dependence can occur. This results in unpleasant side effects (such as agitation and nausea) if opioid medications are suddenly stopped. This study aims to test the use of the drug ondansetron to reduce the symptoms associated with opioid withdrawal and to prevent the progression of opioid physical dependence, thereby allowing future investigators to better test the role of physical dependence in the development of addiction and also possibly improving acceptance of abstinence-based programs for addiction.
This study will be split into two separate investigations, aim 1 and aim 2.
Study aim 1 (Prevention of Opioid Withdrawal) will investigate whether ondansetron, a
5HT3-receptor antagonist, can reduce or prevent withdrawal signs and symptoms in patients
physically dependent on opioids to treat chronic back pain. In this aim, study participants
will be titrated onto sustained release oral morphine for 30 days after which time they will
return to the lab to undergo naloxone-induced withdrawal with either 8 mg ondansetron
pre-treatment (30 min prior to naloxone-induced withdrawal) or placebo. Participants will
then return to their titrated dose of oral morphine for one week before returning for the
second study session in which they will receive the opposite pre-treatment (8 mg ondansetron
or placebo) 30 minutes prior to naloxone-induced withdrawal. Objective opioid withdrawal
score (OOWS), subjective opioid withdrawal score (SOWS) and Profile of Mood States (POMS)
will be assessed at baseline and five or seven times during the study sessions at 30 and 37
days post titration. Beck Depression Inventory, Roland-Morris Questionnaire and State-Trait
Anxiety Inventory and VAS Pain Score will be assessed at baseline as well as at both study
sessions (30 and 37 days post titration).
Study aim 2 (Prevention of Physical Dependence) will investigate whether ondansetron, a 5HT3
receptor antagonist, can prevent physical dependence in patients taking opioids chronically
for controlling chronic back pain. Participants will taper onto sustained release oral
morphine for 10 days then will maintain the effective dose for twenty days (total of 30 days)
while simultaneously taking 8 mg ondansetron or placebo three times daily with morphine dose.
After 30 days of morphine plus 8 mg ondansetron or placebo, study participants will return to
the lab to undergo naloxone-induced withdrawal. OOWS, SOWS, POMS, pain visual analogue scale
(VAS), Beck Depression Inventory and Roland Morris Disability Index will be administered at
baseline and at the beginning of each study session (30 days post titration). Furthermore
OOWS, SOWS and POMS will be administered twice during the first study session and at least
five times during the second study session (Day 30): at the beginning of the session, after
IV insertion, and after naloxone-induced opioid withdrawal.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04080037 -
Assessing Opioid Care Practices Using CPV Patient Simulation Modules
|
N/A | |
Completed |
NCT04126083 -
Lofexidine for Adults Undergoing Lumbar Spine Surgery
|
Phase 4 | |
Completed |
NCT04140955 -
Opioid Tapering After Spine Surgery
|
N/A | |
Not yet recruiting |
NCT03813095 -
Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction
|
Phase 2 | |
Completed |
NCT01262092 -
Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals
|
Phase 2 | |
Completed |
NCT04075214 -
Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal
|
N/A | |
Recruiting |
NCT04325659 -
An Innovative Intervention for OUD Treatment
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03678792 -
Comparison of Three Opioid Detoxification Treatment Regimens
|
Phase 3 | |
Terminated |
NCT04162145 -
BRIDGE Device for Treatment of Opioid Withdrawal
|
N/A | |
Completed |
NCT04238754 -
Oral Cannabidiol for Opioid Withdrawal
|
Phase 1/Phase 2 | |
Recruiting |
NCT05053503 -
Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder
|
N/A | |
Recruiting |
NCT05555485 -
Understanding the Effects of Transcutaneous Auricular Neurostimulation for Treatment of Chronic Pain
|
N/A | |
Active, not recruiting |
NCT03485430 -
Tapering From Long-term Opioid Therapy in Chronic Pain Population. Randomized Controlled Trial With 12 Months Follow up
|
N/A | |
Recruiting |
NCT05790551 -
Suboxone Dispenser for OUD
|
N/A | |
Completed |
NCT03174067 -
Buprenorphine in the Emergency Department
|
Phase 4 | |
Completed |
NCT04731935 -
Novel Earpiece for Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal
|
N/A | |
Completed |
NCT04470050 -
Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06442566 -
ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain
|
Phase 1/Phase 2 | |
Recruiting |
NCT05307458 -
Evaluating the Pharmacokinetics and Patient Outcomes of Buprenorphine Microdosing
|
||
Completed |
NCT03789214 -
Medical Management of Sleep Disturbance During Opioid Tapering
|
Phase 2 |